We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Tiny Injector Speeds Development of Newer, Safer Drugs

By LabMedica International staff writers
Posted on 21 Nov 2009
A palm-sized micro-injector could vastly increase preclinical trials for drug development and genetic engineering, and provide greater control of the process. More...


Researchers at McMaster University (Hamilton, ON, Canada) developed the automated microfluidic micro-injector, which can insert proteins, DNA, and other biomolecules into individual cells at volumes exponentially higher than current procedures, and at a fraction of the cost. The micro-injector has a cell-wide channel cast on a silicon chip that guides cells and embryos to the injection site. A similar channel guides the injection reagent to a needle as thin as 10 micrometers--one-tenth the diameter of a human hair. A buckling method is used to drive the needle through a cell's pliable outer membrane accurately and to the proper depth. The injection dosage is controlled electrically, as is monitoring of the needle's position. The researchers have also developed methods to sharpen the needle, ensuring minimal injection damage or interference to the cell. Notably absent is the need for a microscope or optical magnification to conduct the process, which is required for manual injection and to monitor transfection methods. The microfluidic device also allows easy integration of postprocessing operations, including cell sorting and the testing of cell viability on the same chip.

"This device is to drug discovery what the assembly line was to the automobile or the silicon chip to information technology,” said lead author Ravi Selvaganapathy, Ph.D., an assistant professor of mechanical engineering at McMaster. "It turns what was a complex, resource-intensive process available to a few into an automated, predictable, reliable, and low-cost system accessible to almost anyone.”

"Almost every researcher would be able to have this device at their disposal in their own labs,” added Professor Selvaganapathy. "The micro-injectors can easily be run in parallel and allow for scientists to test far greater combinations of materials in a much shorter time than current processes. It also makes it more feasible to pursue drug discovery for many so-called neglected diseases.”

The micro-injector also holds great promise for in vitro fertilization (IVF), as it provides far greater accuracy and control than current manual injection procedures, which have high rates of failure, require trained expertise, and can be time intensive.

Related Links:
McMaster University






Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.